| Loy, Clement |
| Active, not recruiting | 2 | 252 | Europe, Canada, US, RoW | PTC518, Placebo | PTC Therapeutics, PTC Therapeutics, Inc. | Huntington Disease | 02/25 | 08/25 | | |
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease |
|
|
| Completed | 1/2 | 47 | Europe, Canada, RoW | WVE-003 | Wave Life Sciences Ltd. | Huntington Disease | 05/24 | 05/24 | | |
| Colman, Peter C |
| Recruiting | 3 | 450 | Europe, RoW | Fenofibrate, Inert lactose placebo | University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc | Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies | 12/24 | 12/25 | | |
| Toussaint, Nigel |
NCT06598631: Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease |
|
|
| Terminated | 2 | 8 | Europe, Japan, US, RoW | Volenrelaxin, LY3540378, Placebo | Eli Lilly and Company | Chronic Kidney Disease | 12/24 | 12/24 | | |
| Goldin, Eran Mr |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03390322: Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients |
|
|
| Completed | N/A | 31 | RoW | DiaGone™ | Digma Medical Ltd. | Diabetes Mellitus, Type 2 | 08/24 | 08/24 | | |
| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
| Recruiting | 3 | 200 | RoW | Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) | Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd | Hyperkalemia, Renal Insufficiency, Chronic | 12/25 | 03/26 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) |
|
|
| Active, not recruiting | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 05/28 | 05/28 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Active, not recruiting | 3 | 20 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/26 | 11/26 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 10/28 | | |
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Recruiting | 2/3 | 310 | Europe, Japan, US, RoW | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo | CSL Behring, Commercial/Industry, CSL | Acute-graft-versus-host Disease | 09/25 | 03/27 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Recruiting | 2/3 | 2310 | Europe, Canada, Japan, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | 12/28 | 12/28 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Active, not recruiting | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 12/25 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 127 | Canada, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
|
|
| Completed | 1 | 10 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 09/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Completed | 1 | 12 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 10/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | CSL040, Placebo | CSL Behring | Disease Driven by Complement Activation | 04/25 | 04/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
| Orr, Carolyn |
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease |
|
|
| Completed | 1/2 | 47 | Europe, Canada, RoW | WVE-003 | Wave Life Sciences Ltd. | Huntington Disease | 05/24 | 05/24 | | |
| Christensen, Britt |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Kern, Johannes |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
| Campbell, Bruce |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer |
|
|
| Terminated | 1 | 10 | US | HB-201 IV | Hookipa Biotech GmbH | HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer | 11/23 | 11/23 | | |
| Not yet recruiting | N/A | 30 | RoW | Magnetically enhanced diffusion, PULSE Nanomed System | University of Melbourne, Monash University, Euphrates Vascular, Inc. | Ischemic Stroke, Stroke | 12/26 | 03/27 | | |
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery |
|
|
| Recruiting | 3 | 90 | Europe | CSL511 Fibrinogen concentrate (human), Cryoprecipitate | CSL Behring | Acquired Fibrinogen Deficiency | 09/26 | 10/26 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Active, not recruiting | 1 | 44 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 06/26 | 06/26 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Terminated | 1 | 1 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 09/25 | 09/25 | | |
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant |
|
|
| Not yet recruiting | N/A | 200 | NA | Gilteritinib, ASP2215, XOSPATA® | Astellas Pharma Singapore Pte. Ltd. | Acute Myeloid Leukemia | 06/25 | 06/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Tang, Wen |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease |
|
|
| Recruiting | N/A | 239 | RoW | Ustekinumab, Stelara | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd. | Crohn Disease, Stricture; Bowel, Intestinal Stricture | 08/26 | 08/27 | | |
| Brodtmann, Amy G |
| Completed | 3 | 804 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 10/24 | 10/24 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | N/A | 1000 | RoW | Venepuncture | Monash University, Eastern Health, University of Melbourne, Wake Forest University, Deakin University, The Florey Institute of Neuroscience and Mental Health, Invitae Corporation, Redenlab | Neurodegenerative Diseases, Dementia | 12/25 | 12/27 | | |
| Nicholls, Kathleen |
| Active, not recruiting | 1/2 | 34 | Europe, Canada, US, RoW | ST-920 | Sangamo Therapeutics | Fabry Disease | 04/25 | 09/25 | | |
| Zhong, Jie |
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT01613053: Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination |
|
|
| No Longer Available | N/A | | RoW | Glivec | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumor | | | | |
| Digre, Kathleen |
NCT06395285: Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients |
|
|
| Not yet recruiting | 1 | 12 | US, RoW | DF-003 | Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) | ROSAH | 08/25 | 11/25 | | |
| Macrae, Finlay |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Jiang, Yi |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Completed | 3 | 359 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 08/24 | 08/24 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
| Mocherla, Bharat |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
| Terminated | 3 | 1027 | Europe, Canada, Japan, US, RoW | Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo | Biogen, Biogen Idec Research Limited | Alzheimer's Disease | 08/24 | 08/24 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 410 | Europe, Japan, US, RoW | LY3556050, Placebo | Eli Lilly and Company | Diabetic Peripheral Neuropathy | 07/25 | 07/25 | | |
